SPRAVATO® (esketamine) CIII nasal spray is the S-enantiomer of racemic ketamine. SPRAVATO® is an FDA-approved nasal spray for TRD and MDSI. Ketamine infusion has not been approved by the FDA to treat depression. There are no head-to-head studies comparing esketamine and ketamine infusion. Both SPRAVATO® and ketamine are Schedule III controlled substances under the U.S. Controlled Substances Act.